Quantcast
Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to ETFdb.com. Please help us personalize your experience.

Select the one that best describes you
ALERT

What Does the Rise of Robo-Advisors Mean for the Traditional Asset Management Industry?

Etfdb logo
  • ETF
  • XPH
    Pricing Data
    $41.49
    Change: $0.43 (-0.01%)
    Time: 04/21/17
    Previous Close: $41.92
  • Category
  • Health & Biotech Equities
Last Updated:

Profile

Vitals

Trading Data

Open: - Volume -
Day Lo - Day Hi -
  • 52 Week Lo: $36.47
  • 52 Week Hi: $47.62
  • AUM: $457.0 M
  • Shares: 10.9 M

Investment Themes

Historical Trading Data

  • 1 Month Avg. Volume: 122,070
  • 3 Month Avg. Volume: 190,561

Alternative ETFs in the Health & Biotech Equities Category

Sign Up for Pro to Unlock Data Sign Up
Type Ticker Expense Ratio Assets Avg. Daily Vol YTD Return
Cheapest
Largest (AUM)
Most Liquid (Volume)
Top YTD Performer

Analyst Report

This ETF is one of several options for investors looking to establish exposure to the U.S. pharmaceutical industry, a sub-sector of the health care space that can post big returns during periods of consolidation or as a result of advancements in medicine. Given this narrow focus, XPH probably doesn't belong in a long-term portfolio, though it may be useful for covering a corner of the domestic equity market that receives minimal weight in most portfolios. XPH is noteworthy because of the methodology employed by the underlying index; as an equal-weighted benchmark, this fund offers balanced exposure to the pharma sector, avoiding the potential pitfalls of cap-weighted benchmarks. This equal-weighted methodology distinguishes XPH from other pharma ETFs, such as PJP, PPH, and IHE.

Realtime Rating

Sign Up for Pro to Unlock Data Sign Up

Realtime Rating Summary

The adjacent table gives investors an individual Realtime Rating for XPH on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.

Compare to another ETF

View the Category Report

XPH Overall Realtime Rating:

A+ Overall Rated ETF:

Metric Metric Realtime Rating A+ Metric Rated ETF
Liquidity B n/a
Expenses A- n/a
Performance
Volatility
Dividend
Concentration

Knowledge Centers

XPH In-Depth Analysis

The following tables and charts contain in-depth metrics for this ETF and compare it to similar peer ETFs within its ETFdb.com Category.

XPH Holdings

Filings Data as of: Apr 17, 2017
Sign Up for Pro to Unlock Data Sign Up

Concentration Analysis

This section compares how balanced and deep this ETF is relative to the peer group ETFdb.com Category.

Number of Holdings
Rank:
38
Category Low
Category High
% Assets in Top 10
Rank:
45.70%
Category Low
Category High
% Assets in Top 15
Rank:
66.02%
Category Low
Category High
% Assets in Top 50
Rank:
95.56%
Category Low
Category High

Asset Allocation

Asset Percentage
Common equity 100.0%

Sector Breakdown

Sector Percentage
Healthcare 100.0%

Market Cap Breakdown

Market Cap Percentage
Large cap 34.32%
Small cap 26.45%
Micro cap 21.41%
Mid cap 17.82%

Region Breakdown

Region Percentage
North America 85.11%
Europe 14.89%

Market Tier Breakdown

Region Percentage
United States 85.11%
Developed Markets (ex-US) 14.89%

Country Breakdown

Country Percentage
United States 85.11%
Ireland 13.74%
United Kingdom 1.15%

XPH Expenses & Fees

This section compares the cost efficiency of this ETF to peers in the same ETFdb.com Category.

Sign Up for Pro to Unlock Data Sign Up

Expenses Ratio Analysis

ETF Average
0.571%
ETF Wtd. Average
0.24%
Category Average
0.48%
Expense Ratio
Rank:
0.35%
Category Low
Category High

Commission Free Trading

This ETF is not currently available for commission free trading on any platforms.

Category Commission Free Trading

There are 3 other ETFs in the Health & Biotech Equities ETFdb.com Category that are also eligible for commission free trading:

XPH Performance

This section shows how this ETF has performed relative to its peer group ETFdb.com Category.

1 Week Return
Rank:
-1.71%
Category Low
Category High
4 Week Return
Rank:
1.10%
Category Low
Category High
13 Week Return
Rank:
8.19%
Category Low
Category High
26 Week Return
Rank:
-1.65%
Category Low
Category High
Year to Date Return
Rank:
6.20%
Category Low
Category High
1 Year Return
Rank:
-6.91%
Category Low
Category High
3 Year Return
Rank:
-1.82%
Category Low
Category High
5 Year Return
Rank:
65.75%
Category Low
Category High

Brought to You by Mitre Media


Charts

The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.

The following chart also includes the option to compare the performance of XPH relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.

XPH Valuation

This section shows how the P/E multiple of this ETF compares to the peer group ETFdb.com Category.

Sign Up for Pro to Unlock Data Sign Up
P/E Ratio
Rank:
11.32
Category Low
Category High

As of Aug 25 2016

XPH Dividend

This section shows how the dividend yield of this ETF compares to the peer group ETFdb.com Category.

Sign Up for Pro to Unlock Data Sign Up
Dividend
$0.03
Dividend Date
2017-03-17
Annual Dividend Rate
$0.25
Annual Dividend Yield
Rank:
0.59%
Category Low
Category High

As of Aug 25, 2016

XPH Technicals

Sign Up for Pro to Unlock Data Sign Up

Volatility Analysis

This section shows how the volatility of this ETF compares to the peer group ETFdb.com Category.

5 Day Volatility
Rank:
310.71%
Category Low
Category High
20 Day Volatility
Rank:
15.36%
Category Low
Category High
50 Day Volatility
Rank:
16.56%
Category Low
Category High
200 Day Volatility
Rank:
18.53%
Category Low
Category High
Beta
Rank:
1.26
Category Low
Category High
Standard Deviation
Rank:
2.43%
Category Low
Category High

Technicals

  • 20 Day MA: $41.96
  • 60 Day MA: $41.35
  • MACD 15 Period: -0.46
  • MACD 100 Period: 0.97
  • Williams % Range 10 Day: 84.83
  • Williams % Range 20 Day: 68.58
  • RSI 10 Day: 43
  • RSI 20 Day: 49
  • RSI 30 Day: 50
  • Ultimate Oscillator: 47

Bollinger Brands

  • Lower Bollinger (10 Day): $41.22
  • Upper Bollinger (10 Day): $42.98
  • Lower Bollinger (20 Day): $41.05
  • Upper Bollinger (20 Day): $42.84
  • Lower Bollinger (30 Day): $40.76
  • Upper Bollinger (30 Day): $42.74

Support & Resistance

  • Support Level 1: $41.25
  • Support Level 2: $41.01
  • Resistance Level 1: $41.81
  • Resistance Level 2: $42.13

Stochastic

  • Stochastic Oscillator %D (1 Day): 48.84
  • Stochastic Oscillator %D (5 Day): 38.83
  • Stochastic Oscillator %K (1 Day): 50.44
  • Stochastic Oscillator %K (5 Day): 39.40

Fact Sheet

Fact sheets are issued by the ETF provider and framed by ETFdb.com. Information contained within the fact sheet is not guaranteed to be timely or accurate.

2014 Morningstar, Inc. All Rights Reserved. The information contained herein: ( 1 ) is proprietary to Morningstar and/or its content providers; ( 2 ) may not be copied or distributed; and ( 3 ) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Source: LSEG Information Services (US), Inc. (“LSEG”) © LSEG 2016. All rights in the XTF data, ratings and / or underlying data contained in this communication (“the XTF information”) vest in LSEG and/or its licensors. Neither LSEG nor its licensors accept any liability arising out of the use of, reliance on or any errors or omissions in the XTF information. No further distribution of the XTF information is permitted without LSEG’s express written consent. LSEG does not promote, sponsor or endorse the content of this communication.